哌拉西林他唑巴坦治疗COPD合并吸入性肺炎的疗效与安全性评价

摘要

Objective: To evaluate the ef icacy and safety of piperacil in-tazobactam in the treatment of patients with COPD complicated by aspiration pneumonia. Metheds: 47 patients with COPD complicated by aspiration pneumonia who were treated with piperacil in- tazobactam were enrol ed in this study by retrospective analysis. The treatment duration was 7-14 days.The clinical ef icacy, bacterial eradication rate, and safety were analyzed. Results: The total effective rate of piperacil in-tazobactam was 78.7% and the curative rate was 29.8%. The bacterial eradication rate was 75.9% while the rate of adverse effect was 4.3%. Conclusion: Piperacil in-tazobactam is effective and safe in the treatment of patients with COPD complicated by aspiration pneumonia.%目的：评价哌拉西林-他唑巴坦治疗COPD合并吸入性肺炎（AP）的临床疗效和安全性。方法回顾性分析哌拉西林他唑巴坦治疗47例 COPD合并 AP患者的临床疗效、细菌学评价和安全性分析。结果哌拉西林他唑巴坦治疗COPD合并AP患者有效率为78.7%，痊愈率29.8%，细菌清除率为75.9%，不良反应发生率为4.3%。结论哌拉西林-他唑巴坦治疗COPD合并AP患者疗效好，安全性高。